Pharma Deals Review, Vol 2008, No 96 (2008)

Font Size:  Small  Medium  Large

Daiichi Sankyo Boosts Oncology Portfolio with Acquisition of Biotech, U3 Pharma

Helen Scrutton

Abstract


Daiichi Sankyo is to acquire German oncology biotech, U3 Pharma, for €150 M (US$234 M), boosting the Japanese company’s biologics pipeline.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.